US Pharm 2010;35(11):84.

Due to the increasing availability of generic antihypertensive agents in the coming decade, the hypertension drug market is projected to decline from $26 billion in 2009 to $23 billion in 2019 in the U.S. France, Germany, Italy, Spain, United Kingdom, and Japan, according to a report by Decision Resources, a pharmaceutical and health care research firm.

Novartis's Diovan/Tareg is expected to suffer the greatest decline; its sales are projected to decrease more than $1 billion in 2013, following the entry of generic versions of the drug. By 2019, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium channel blockers, and diuretics will all be subject to generic competition, the report concludes.